INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES
[ISSN: 0975-4725; CODEN(USA): IJPS00]
Journal Homepage: https://www.ijpsjournal.com

OPEN ACCESS

Review Article

Integrated Transdermal Therapeutic Systems: Technologies, Applications and Challenges

Ajay Joseph*[1], Aiswarya Raj P.[2], Dileep K. J.[3]

[1] *Department of Pharmaceutics, College of Pharmaceutical Sciences, Government Medical College, Thiruvananthapuram, Kerala, India-695011*
[2, 3] *Department of Pharmaceutics, College of Pharmaceutical Sciences, Government Medical College, Thiruvananthapuram, Kerala, India-695011.*

ARTICLE INFO

Published: 08 Jun. 2026
Keywords:
Microneedles, iontophoresis, electroporation, wearable electronics, smart biomaterials
DOI:
10.5281/zenodo.20595392

ABSTRACT

Integrated Transdermal Drug Delivery Systems have emerged as promising alternatives to conventional drug delivery systems, facilitating controlled, targeted, and minimally invasive therapeutic delivery. Recent advancements in this area have led to integration of a variety of enhancement strategies, such as microneedles, iontophoresis, electroporation, nanocarriers, and smart biomaterials, which have the potential to overcome the limitations of traditional transdermal patches, like poor skin permeability and limited drug loading capacity. These systems combine physical, electrical and chemical enhancement mechanisms to improve drug permeation, therapeutic efficacy, and patient compliance. Integration of smart biomaterials, wearable electronics, and responsive delivery mechanisms has further enabled the development of multifunctional therapeutic platforms that are also able to monitor physiological conditions, and support personalized medicine. Recent advancements have expanded the applications of these systems in the treatment of chronic diseases, cancer therapy, vaccination, and regenerative medicine. This review focuses on the technologies, recent developments, and therapeutic applications of integrated systems. In addition, the limitations and current challenges associated with these systems, including biocompatibility, formulation stability, scalability, and regulatory concerns are also reviewed. Finally, future perspectives on the development of safer, smarter, and more efficient integrated systems are also highlighted.

INTRODUCTION

Transdermal Drug Delivery Systems have emerged as a desirable alternative to conventional

***Corresponding Author:** Ajay Joseph
Address: *, College of Pharmaceutical Sciences, Government Medical College, Thiruvananthapuram, Kerala, India-695011*
Email : ajay32954@gmail.com

Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

oral and parenteral drug administration methods due to their ability to offer painless delivery, enhanced patient compliance, circumvention of hepatic first-pass metabolism, and long-lasting therapeutic benefits. However, traditional transdermal patches face a challenge in the form of the barrier characteristics of stratum corneum, that hinders the movement of large, hydrophilic, and charged molecules over the skin.[1] Integrated transdermal therapeutic systems address this demerit by combining traditional transdermal delivery methods with several augmentation technologies.

The development of these systems has increased due to recent developments in microneedles, iontophoresis, electroporation, ultrasound assisted delivery, conductive hydrogels, wearable electronics as well as smart sensing platforms. Along with improving transdermal penetration, these devices also facilitate programmable drug delivery, real-time monitoring, and remote healthcare management. Furthermore, integrated transdermal systems are being fabricated as multifunctional theranostic platforms, which are capable of sensing, diagnosis, and treatment all at once.[2]

Microneedle based integrated systems have gathered significant interest due to their ability to create temporary microchannels in the skin by gently piercing the stratum corneum, which make drug delivery more effective. Various types of microneedles, such as solid, coated, hollow, dissolving, porous, and hydrogel forming microneedles, have been studied for integration with electrically assisted technologies such as iontophoresis and electroporation. [2,3,4]

Investigations and studies on integrated transdermal therapeutic systems on their applications like insulin delivery, vaccine administration, cancer therapy, chronic illness management, responsive medication delivery etc., are being done at an increasing rate. These systems have been further developed into intelligent healthcare platforms that provide remote patient monitoring and personalized medicine by integration of wearable electronics, smartphone-based control, and wireless communication. [3]

1. Skin As a Barrier to Transdermal Drug Delivery

The skin comprises epidermis, dermis, and the hypodermis, which makes it the body's main line of defense. The stratum corneum of epidermis acts as the barrier to the transdermal permeation of a drug, due to its limited permeability and dense, keratinized structure. [5,6] This barrier prevents the effective transport of the majority of hydrophilic as well as large molecular weight drugs, posing a challenge to the use of conventional transdermal patches.

Passive diffusion of drugs is possible only through undamaged skin, provided they have beneficial physicochemical characteristics like low molecular weight, appropriate potency, and sufficient lipophilicity. Permeation enhancement techniques have been developed to circumvent stratum corneum, so as to increase boost drug delivery into deeper skin layers or systemic circulation.

Integrated transdermal systems serve the same purpose by employing physical augmentation techniques like microneedles, iontophoresis, electroporation, ultrasound, and heat treatments.[6] The synergistic combination of such technologies enhances transdermal flux as well as distribution of biomacromolecules, peptides, proteins, vaccines, and nucleic acids, which are otherwise challenging to administer by traditional transdermal patches.

2. Technologies Used in Integrated Transdermal Therapeutic Systems

2.1 Microneedle based systems

Microneedles are micron-scale needle structures that provide minimally invasive drug delivery, by piercing the stratum corneum without going through blood vessels and pain receptors. Due to the creation of such microchannels, therapeutic substances can be transported more effectively across the skin. Various types of microneedles, namely solid, coated, hollow, dissolving, porous, and hydrogel forming microneedles, have been created for this purpose. [2,4]

Hollow microneedles are very useful for integrated systems due to their resemblance to hypodermic needles, allowing active fluid transmission into the skin. Porous microneedles are good for integration with iontophoresis, due to formation of interconnected microchannels for drug permeation and ion transport. Dissolving microneedles, which are made of biodegradable polymers, eliminate biohazardous waste and regulates drug release.[8]

Recent studies have shown successful integration of microneedles with wearable electronics, conductive hydrogels, and wireless systems for controlled and on-demand drug delivery. [9]

2.2 Iontophoresis-Assisted Systems

Iontophoresis is a non-invasive permeation enhancement method which uses small electric currents to push charged drug molecules through the skin. Precise control over drug delivery can be made possible by varying the intensity and duration of current. [8] Since microneedles forms microchannels through the stratum corneum, skin resistance is lowered, and combining this with iontophoresis further improves transdermal delivery. This integration has proven to be useful in successfully delivering vaccines, insulin, analgesics, and therapeutic macromolecules. [10,11]

Moreover, combination of microneedles and conductive hydrogels with wearable iontophoretic systems have enables administer drugs programmable and controlled by smartphones. These technologies enhance personalized therapy, user convenience, and delivery efficiency. [3]

2.3 Electroporation-Assisted Systems

Electroporation applies brief and high-voltage electric pulses to stratum corneum, which temporarily disrupts lipid bilayers to increase skin permeability. Integration of microneedles with electroporation have shown to improve the transport of proteins, DNA vaccines and macromolecules.[12] Combining electroporation with microneedles gives twofold enhancement by physical disruption of the epidermal barrier along with electrical boosting of membrane permeability.

2.4 Ultrasound-Assisted Transdermal Systems

Ultrasound-assisted drug delivery, also called sonophoresis, uses ultrasonic waves to improve transdermal delivery. This disrupts the lipid structure of stratum corneum, promoting molecular transport across the skin. When compared to passive diffusion methods, combining ultrasound, iontophoresis and dissolving microneedles have shown increased delivery efficiency and faster drug penetration. Investigations on multifunctional devices that combine these methods are being conducted more and more. [13]

2.5 Wearable and Smart Transdermal Systems

Recent integrated systems comprise wearable electronics, flexible sensors, conductive hydrogels, wireless communication modules, and smartphone apps.[14] These technologies enable personalized healthcare management, programmed drug release and remote monitoring.[2]

A research study showed on-demand delivery of insulin, glucagon and chemotherapeutic drugs using a wearable device that combined iontophoresis with electro-responsive hydrogels and polymeric microneedles. This technique provided programmed drug release by electrically controlled hydrogel contraction.[9]

Similarly, smartphone-controlled iontophoresis driven microneedle systems have enabled the administration of analgesics in a controlled and long-lasting manner in a variety of dose options like pulse and sustained release therapy. [3]

3. Applications Of Integrated Transdermal Therapeutic Systems

3.1 Diabetes Management

Integrated transdermal devices have shown great promise in management of diabetes through regulated insulin delivery. Combining iontophoresis and responsive hydrogels with smart microneedle technologies provide on-demand insulin delivery while significantly reducing patient discomfort from repeated injections by parenteral route. [9]

3.2 Vaccine Delivery

Integrated systems have also demonstrated effective transdermal vaccine delivery by addressing the drawbacks of traditional intramuscular injections. This is shown to be successful due to the presence of many antigen-presenting cells in the skin. Research studies have shown improvements in patient compliance as well as facilitating self- administration by iontophoresis driven microneedle patches, which also elicit more robust immune response compared to conventional intramuscular vaccinations. [10]

3.3 Pain Management and Local Anesthesia

Integrated microneedle-iontophoresis devices have been researched extensively for transdermal local anesthesia and pain management. Quick onset and sustained analgesic effects have been demonstrated by smartphone-controlled, lidocaine-loaded, fiber-based microneedle patches. These systems show better patient comfort and controlled dosage while lowering risks of infection compared to injectable anesthetics.[3]

3.4 Cancer Therapy

Integrated transdermal therapeutic systems have also been explored for targeted cancer treatment and localized chemotherapy. Successful tumor suppression has been demonstrated in preclinical research studies by wearable transdermal devices that enable high dose administration of chemotherapy drugs. [9]

3.5 Theranostic and Remote Healthcare Applications

Modern integrated systems have combined biosensing and therapeutic functions into a single wearable platform. Management of chronic diseases and providing personalized healthcare have been made possible by remote-controlled hollow microneedle systems that can simultaneously sense lactate, pH and glucose, and dispense drugs. These systems facilitate point-of-care medical applications, telemedicine and remote monitoring. [2]

4. Challenges To Integrated Transdermal Therapeutic Systems

Even though integrated transdermal therapeutic systems have made significant advances, their broad commercialization and clinical acceptance is restricted by a number of scientific, technological, clinical and regulatory obstacles.

Integration of technologies into a single platform increases its complexity, while questions about long term stability, manufacturing scalability, patient safety and device reproducibility continue to rise.

4.1 Skin Barrier Limitations and Variable Skin Permeability

Stratum corneum of the skin still remains the greatest obstacle to effective transdermal administration. Although integrated systems improve skin permeability by combining permeation enhancement technologies, individual differences in skin features can impact the effectiveness of drug delivery. A number of factors like skin thickness, hydration level, age, anatomical site, ethnicity, disease state, and environmental exposure can influence transport of drugs across the skin.[11] For example, resistance to drug permeation is greater in thick skin areas like the palm and sole when compared to thin skin areas like forearm. Also, electrical conductivity and drug absorption may be affected by ill or damaged skin. Dose standardization and reproducibility become more difficult by this variability.

Similarly, it is a challenge to maintain a constant delivery rate in electrically assisted systems due to variation in skin impedance throughout treatment, due to hydration and pore development. So, patient specific tailoring is necessary to obtain consistent treatment results. [8]

4.2 Limited Drug Loading Capacity

One of the main drawbacks of integrated transdermal systems, especially dissolving and coated microneedle systems, is limited drug loading capacity. Therapeutic compounds like proteins, peptides, biologics and chemotherapeutic drugs require high doses that makes it challenging to combine these into small transdermal devices.

In case of dissolving microneedles, the matrix volume restricts the amount of drug being encapsulated. As for coated microneedles, high dose drug loading is impacted by limited surface area. While hollow and porous microneedles can overcome these issues, they are affected by mechanical fragility and manufacturing complexity. [2,3]

Additionally, maintenance of consistent drug delivery is still difficult. Drug agglomeration, crystallization or leakage during storage may impact accurate distribution and therapeutic efficiency.

Transport of macromolecules like insulin, vaccines, antibodies and nuclei acids present another difficulty. During production, sterilization and storage, these biomolecules can lose their bioactivity due to their extreme sensitivity to environmental factors.[10]

4.3 Mechanical Fragility and Structural Failure of Microneedles

Microneedles must have enough mechanical strength for piercing the skin without breaking, bending or deforming. However, use of biodegradable polymer, hydrogels or dissolving materials during manufacture compromise the mechanical robustness of microneedles.

Mechanical failure of microneedles may result in incomplete skin penetration, uneven drug distribution, and possible retention of shattered pieces by the skin. This can raise questions about risk of infection, inflammation and safety.

Moreover, hollow microneedles are vulnerable to structural collapse due to their intricate geometry and thin walls. Porous microneedles may also be structurally weak due to their linked pore patterns. Maintenance of the ideal ratio of porosity, drug permeability and mechanical integrity still pose a great challenge to the manufacture of these systems.[8]

4.4 Skin Irritation, Inflammation, and Patient Safety

Although integrated transdermal systems are considered to be minimally invasive, prolonged administration can result in erythema, edema, irritation, itching or local inflammation. Application of excessive current density or voltage, electrically assisted systems, like iontophoresis and electroporation may lead to burns or irritations in the skin. This can also harm the surrounding tissues and compromise the integrity of the skin.[12] Also, repeated insertion of microneedles into skin can result in inflammatory reactions, especially in sensitive skin. Persons with diabetes, psoriasis, eczema or weak immune systems may heal much slower or become more prone to infections.

Another challenge is the biocompatibility of the electrode components, hydrogels, adhesives and conductive materials. Prolonged exposure to some conductive polymers or metallic objects can give rise to allergic or cytotoxic reactions. [8] It is important to use safe current densities, biocompatible materials and necessary sterilizing procedures for long term clinical application.

4.5 Challenges Associated with Electrical Integration

Integrated systems that use electroporation or iontophoresis require reliable electrical performance. However, some engineering difficulties may arise when electrodes, conductive hydrogels, batteries and flexible electronics are integrated into wearable platforms. Throughout treatment, pore development and hydration results in constant variation of the skin's electrical resistance. This affects current distribution, which may lead to uneven drug transport.[12]

Besides this, power consumption remains another challenge. Wearable devices must have lower battery weight and gadget size while maintaining functional efficiency. Excessive power consumption can hinder patient convenience and portability of these devices. Also, it is even more challenging to reduce the size of electronic components without sacrificing functionality or security of these devices. Flexible electronic components must be able to endure frequent body movements, bending and stretching without experiencing electrical breakdowns.[13]

4.6 Complexity of Device Fabrication and Integration

Integrated transdermal systems involve combining microneedles, drug reservoirs, conductive materials, sensors, wireless modules and microfluidic systems onto a single platform. These require advanced production processes due to their complexity in fabrication and assembly.

At microscale dimensions, precise alignment and integration of functional components is a challenge. Small fabrication errors can impact device performance and reproducibility. Moreover, many of the fabrication techniques being used today are labor-intensive, time-consuming, and difficult to standardize, making large scale production difficult.[2]

4.7 Drug Stability and Storage Problems

Integrated transdermal systems are capable of delivering sensitive macromolecules like insulin, proteins, vaccines, peptides and nucleic acids. These substances are prone to oxidation, pH changes, temperature, moisture as well as mechanical stress. Manufacturing procedures that use heat, solvents, UV light etc., may decrease the stability and bioactivity of these substances. Leakage, dehydration of hydrogel and polymer degradation are additional issues with long term storage of these devices.

Also, sterility during production and storage is crucial especially for microneedle-based devices that pierce the skin barrier. Poor storage conditions may lead to the risk of microbial contamination, that compromise patient safety.[10] So, stabilizers and protective encapsulation methods are crucial for good shelf life and therapeutic reliability.

4.8 Inconsistent and Uncontrolled Drug Release

Obtaining an accurate and consistent drug release pattern is another challenge to integrated transdermal systems. Drug diffusion can be affected by factors like skin resistance, moisture, current distribution, penetration depth of microneedles, as well as environmental factors. Passive diffusion shows delayed onset and little control over release kinetics as common characteristics. Even if iontophoretic and electro-responsive techniques gives control over drug release, Changes in electrical parameters can impact delivery rates.[8]

Moreover, stimuli responsive systems may also show partial response or delayed activation under physiological circumstances. Mechanical deformation and body movement also can affect drug release behavior in wearable devices.[9]

4.9 Regulatory and Clinical Translation Challenges

Since integrated systems combine pharmaceutical formulations, medical devices, biomaterials and electrical components, regulatory approval becomes complicated. Regulatory bodies must thoroughly evaluate the safety, efficacy, sterility, biocompatibility and long-term dependability of such devices.

Moreover, standardized testing procedures for integrated wearable devices are yet to be developed, making regulatory paths unclear. Requirement of large-scale clinical trials are necessary for assessing therapeutic efficacy and long-term patient compliance. Since these systems involve both drugs and devices, multidisciplinary regulatory assessment is essential.[12]

4.10 Data Security and Privacy Concerns in Smart Wearable Systems

Modern transdermal systems incorporate wireless connection, smartphone apps, cloud-based monitoring and biosensing technologies at an increasing rate. Even if these devices increase personalized care, they also raise questions on privacy and cybersecurity. For integrated transdermal systems, strong encryption, data protection, and dependable connectivity are very important since issues like wireless communication flaws, manipulation of remote drug delivery parameters, and unauthorized access to patient date can jeopardize patient safety.[2]

Moreover, ethical issues regarding ongoing health monitoring and AI-driven therapeutic decision making must also be resolved before widespread implementation of such systems.

4.11 Cost and Commercialization Limitations

Advanced integrated systems frequently use expensive biomaterials, complex production methods, microelectronics and wireless communication technologies.[2] This causes the production costs of such devices to be much higher than that of traditional transdermal patches.

Commercial scaling of such products is often restricted by problems with mass production, quality control, sterilization, packaging and device reproducibility. The need for specialized industrial facilities further increases the financial burden. So, the creation of affordable, scalable, and userfriendly technologies is necessary for widespread clinical deployment of such devices.

4.12 Lack of Long-Term Clinical Evidence

Despite showing encouraging findings by many pre-clinical trials, long term clinical evidence regarding safety and efficacy of integrated transdermal systems are still few. The majority of contemporary research is performed *in vitro* or in animal models, and clinical trials of these systems in human beings are rare. Long term assessment is essential to evaluate chronic skin exposure, frequent use of microneedles, device durability, patient adherence and treatment consistency. More clinical research is necessary before these devices are widely accepted in standard healthcare practice. [9,10]

5. FUTURE PERSPECTIVES

The future of integrated transdermal therapeutic systems requires creation of intelligent, adaptable, and customized healthcare platforms. Enhancement of patient comfort, scalability and device performance can be expected from such systems by developments in biomaterials, additive manufacturing, flexible electronics and nanotechnology.

Artificial Intelligence (AI) and Machine Learning (ML) have the potential to revolutionize future integrated systems. AI-assisted systems can enable predictive drug dosing, adaptive current modulation, real-time physiological monitoring and closed-loop therapeutic control based on patient-specific responses. ML algorithms can evaluate physiological signs and optimize drug delivery, paving way to customized treatment plans.

In the future, wearable theranostic systems may combine biosensors, wireless communication modules, cloud computing and AI-driven analytics to provide remote healthcare management and precision medicine, resulting in smart systems with autonomous diagnosis and treatment capabilities. 3D printing and additive manufacturing technologies are capable of streamlining the rapid prototyping and customized manufacture of transdermal devices with unique geometries. Further, sustainability and long-term usability can be improved by use of self-powered systems and biodegradable materials.

Integrated transdermal therapeutic systems show great promise to revolutionize contemporary healthcare by providing controlled, intelligent, customized and painless drug delivery despite having a number of unresolved issues.

6. CONCLUSION

By creating multipurpose platforms via combination of microneedles, iontophoresis, electroporation, ultrasound, wearable electronics, and responsive biomaterials, integrated transdermal therapeutic systems show a great advancement in contemporary drug delivery. These systems facilitate controlled, minimally invasive as well as customized treatment while overcoming the drawbacks of conventional transdermal delivery.

Recent studies have shown promising uses in cancer therapy, diabetes treatment, pain management, immunization and remote monitoring. The potential of such systems in theranostic and precision medicine is further enhanced by the combination of wearable electronics and smart sensing technologies.

Widespread clinical implementation is still obstructed by issues regarding drug loading, skin safety, device complexity, scalability, power management and regulatory approval. Ongoing interdisciplinary research in material science, biomedical engineering, electronics and pharmaceutical sciences is required for overcoming these challenges.

Future integration of AI and ML into transdermal therapeutic systems is expected to accelerate the development of adaptive, autonomous, and patient specific healthcare that are able to revolutionize personalized medicine.

REFERENCES

1. Alkilani AZ, Nasereddin J, Hamed R, Nimrawi S, Hussein G, Abo-Zour H, Donnelly RF. Beneath the skin: a review of current trends and future prospects of transdermal drug delivery systems. Pharmaceutics. 2022 May 28;14(6):1152.
2. Razzaghi M, Ninan JA, Azimzadeh M, Askari E, Najafabadi AH, Khademhosseini A, Akbari M. Remote‐controlled sensing and drug delivery via 3D‐printed hollow microneedles. Advanced Healthcare Materials. 2024 Sep;13(23):2400881.
3. Wang T, Shi X, Wang Y, Sun H, Sun Y, Wang G, Jiang H. Lidocaine-loaded iontophoresis-driven fiber-based microneedle patch for controllable and long-lasting transdermal local analgesia. Advanced Fiber Materials. 2025 Feb;7(1):281-95.
4. Sen O, Poddar P, Sarkar P, Das S, Manna S. Current advancements in microneedle technology for therapeutic and biomedical applications. Sensors International. 2025 Jan 1;6:100325.
5. Lever WF. Lever's Histopathology of the Skin. Lippincott Williams & Wilkins; 2009.
6. Lopez-Ojeda W, Pandey A, Alhajj M, Oakley AM. Anatomy, skin (integument). InStatPearls [internet] 2022 Oct 17. StatPearls Publishing.
7. Ramadon D, McCrudden MT, Courtenay AJ, Donnelly RF. Enhancement strategies for transdermal drug delivery systems: current trends and applications. Drug delivery and translational research. 2022 Apr;12(4):758-91.
8. Wang R, Wang H, Yao R, Li Y, Manar S, Nie L, Yunusov KE, Pan J, Jiang G. Iontophoresis-driven transdermal drug delivery system based on porous microneedles for hyperuricemia treatment. International Journal of Pharmaceutics. 2025 Feb 25;671:125290.
9. Wang H, Cai R, Wang S, Yang Y, Sheng T, Zhang W, Wang S, You J, Lu Z, Ji K, Jiao Y. A wearable transdermal device for on-demand drug delivery. Matter. 2025 Apr 2;8(4).
10. Zheng Y, Ye R, Gong X, Yang J, Liu B, Xu Y, Nie G, Xie X, Jiang L. Iontophoresis-driven microneedle patch for the active transdermal delivery of vaccine macromolecules. Microsystems & nanoengineering. 2023 Mar 27;9(1):35.
11. Hasan M, Khatun A, Kogure K. Iontophoresis of biological macromolecular drugs. Pharmaceutics. 2022 Feb 26;14(3):525.
12. Abbasi M, Heath B. Iontophoresis and electroporation-assisted microneedles: advancements and therapeutic potentials in transdermal drug delivery. Drug delivery and translational research. 2025 Jun;15(6):1962-84.
13. Bok M, Zhao ZJ, Jeon S, Jeong JH, Lim E. Ultrasonically and iontophoretically enhanced drug-delivery system based on dissolving microneedle patches. Scientific reports. 2020 Feb 6;10(1):2027.
14. Wang G, Moriyama N, Tottori S, Nishizawa M. Recent advances in iontophoresis-assisted microneedle devices for transdermal biosensing and drug delivery. Materials Today Bio. 2025 Apr 1;31:101504.

HOW TO CITE: Ajay Joseph*, Aiswarya Raj P., Dileep K. J., Integrated Transdermal Therapeutic Systems: Technologies, Applications and Challenges, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 6, 2069-2077. https://doi.org/ 10.5281/zenodo.20595392